In a recent clinical trial, treatment with an analog of fibroblast growth factor 21 (FGF21), a representative hepatokine, produced significant improvements in dyslipidemia in humans with obesity and type 2 diabetes [18]. This evidence concerns the gene FGF21 and obesity due to melanocortin 4 receptor deficiency.